To increase the production capacity of Covid-19 vaccines, the Sanofi plant could be called upon to produce the AstraZeneca vaccine.
And other vaccines will also be produced on French industrial sites.
The supply of vaccine to fight against the coronavirus is being organized on a European scale.
Some will even be made in France, as Agnès Pannier-Runacher, the Minister for Industry, announced Friday morning on Europe 1. Given the demand, this is the only way to increase the capacity of production.
>> LIVE -
Coronavirus: follow the evolution of the situation on Friday January 8
Never before have so many vaccines had to be produced so quickly and at the same time in the world.
All production capacities are therefore used and the available French factories will also be called upon.
The Recipharm plant will produce the Moderna vaccine in the Indre et Loire from late February-early March, Delpharm that of Pfizer / BioNTech in its plant in Eure-et-Loire, or even Fareva could produce that of CureVac, s 'he obtains a marketing authorization.
>> READ ALSO
- Vaccine: "the Germans have played the game" of Europe, assures Agnès Pannier-Runacher
Sanofi involved
It's more unprecedented but Sanofi, whose vaccine has been delayed, could also use its own production lines for other suppliers, as confirmed by Agnès Pannier-Runacher, the Minister for Industry on Friday. morning on Europe 1, "if technically it is possible, because a technology transfer to open a site takes time," she said.
"We are working on it," added the minister.
Sanofi could therefore produce the AstraZeneca vaccine.
As for the Sanofi vaccine itself, it could be very promising according to several sources.
It is expected at best for the end of 2021.